Subtopic Deep Dive
Imatinib Mesylate Treatment for PDGFRA-Associated Eosinophilia
Research Guide
What is Imatinib Mesylate Treatment for PDGFRA-Associated Eosinophilia?
Imatinib mesylate treatment for PDGFRA-associated eosinophilia uses the tyrosine kinase inhibitor to target FIP1L1-PDGFRA fusion proteins in hypereosinophilic syndromes, achieving high response rates in fusion-positive patients.
Studies demonstrate imatinib's efficacy in PDGFRA-rearranged eosinophilia, particularly in hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (Rothenberg et al., 2008; 567 citations). Pardanani et al. (2003; 394 citations) identified CHIC2 deletion as a surrogate marker for FIP1L1-PDGFRA fusion, predicting imatinib response in systemic mastocytosis with eosinophilia. Gotlib et al. (2003; 286 citations) outlined diagnostic and management implications of this fusion kinase.
Why It Matters
Imatinib mesylate transformed treatment of PDGFRA-associated eosinophilia by inducing durable remissions in FIP1L1-PDGFRA-positive HES patients, reducing reliance on corticosteroids (Pardanani et al., 2003). This success established kinase inhibitors as precision therapy models in hematologic eosinophilic disorders, guiding classification and response prediction (Gotlib et al., 2003; Klion, 2015). Real-world applications include genetic screening for CHIC2 deletion to select imatinib-responsive cases, improving outcomes in rare eosinophilic syndromes (Valent et al., 2012).
Key Research Challenges
Imatinib Resistance Mechanisms
PDGFRA-mutant clones emerge in long-term treatment, leading to relapse in HES patients (Gotlib et al., 2003). Identifying secondary mutations requires advanced sequencing, complicating management (Klion, 2015). Over 50% of initially responsive cases develop resistance within years.
Predicting Treatment Response
CHIC2 deletion surrogates FIP1L1-PDGFRA but misses rare PDGFRA variants, causing diagnostic errors (Pardanani et al., 2003). Clinical predictors like eosinophil levels vary, hindering patient selection (Roufosse and Weller, 2010). Standardized genetic testing remains inconsistent across centers.
Optimal Dosing Regimens
Low-dose imatinib (100 mg daily) sustains responses, but escalation protocols for resistance lack trials (Klion, 2015). Long-term safety data for eosinophilia subtypes are limited (Ogbogu et al., 2009). Combination with mepolizumab needs validation in PDGFRA-positive cohorts (Rothenberg et al., 2008).
Essential Papers
Eosinophilic gastrointestinal disorders (EGID)
Marc E. Rothenberg · 2004 · Journal of Allergy and Clinical Immunology · 908 citations
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
Peter Valent, Amy D. Klion, Hans‐Peter Horny et al. · 2012 · Journal of Allergy and Clinical Immunology · 744 citations
Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy
Princess U. Ogbogu, Bruce S. Bochner, Joseph H. Butterfield et al. · 2009 · Journal of Allergy and Clinical Immunology · 607 citations
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Marc E. Rothenberg, Amy D. Klion, Florence Roufosse et al. · 2008 · New England Journal of Medicine · 567 citations
Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic...
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman et al. · 2003 · Blood · 394 citations
Abstract Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFRβ- activating mutations. The drug is also active in a subset of pa...
Practical approach to the patient with hypereosinophilia
Florence Roufosse, Peter F. Weller · 2010 · Journal of Allergy and Clinical Immunology · 316 citations
Eosinophils from Physiology to Disease: A Comprehensive Review
Giuseppe A. Ramirez, Mona‐Rita Yacoub, Marco Ripa et al. · 2018 · BioMed Research International · 296 citations
Despite being the second least represented granulocyte subpopulation in the circulating blood, eosinophils are receiving a growing interest from the scientific community, due to their complex patho...
Reading Guide
Foundational Papers
Read Pardanani et al. (2003) first for CHIC2-imatinib link (394 citations), then Gotlib et al. (2003) for fusion diagnostics, followed by Valent et al. (2012) for eosinophilia classification (744 citations).
Recent Advances
Study Klion (2015; Blood, 273 citations) for HES treatment algorithms; Ramirez et al. (2018) reviews eosinophil roles in PDGFRA contexts.
Core Methods
Imatinib inhibits PDGFRA kinase (100 mg/day); diagnostics use RT-PCR/FISH for fusions, CHIC2 deletion; outcomes measured by eosinophil normalization and organ response (Pardanani et al., 2003; Gotlib et al., 2003).
How PapersFlow Helps You Research Imatinib Mesylate Treatment for PDGFRA-Associated Eosinophilia
Discover & Search
Research Agent uses searchPapers for 'Imatinib PDGFRA eosinophilia' to retrieve Pardanani et al. (2003), then citationGraph reveals 394 downstream citations on CHIC2 surrogates, while findSimilarPapers expands to Gotlib et al. (2003) for fusion diagnostics.
Analyze & Verify
Analysis Agent applies readPaperContent to extract response rates from Pardanani et al. (2003), verifies claims via verifyResponse (CoVe) against Klion (2015), and runs PythonAnalysis to plot survival curves from HES cohorts using pandas, with GRADE grading for evidence strength in imatinib efficacy.
Synthesize & Write
Synthesis Agent detects gaps in resistance data post-2015 via gap detection, flags contradictions between mepolizumab and imatinib cohorts (Rothenberg et al., 2008), while Writing Agent uses latexEditText, latexSyncCitations for Pardanani (2003), and latexCompile to generate review sections with exportMermaid for treatment response flowcharts.
Use Cases
"Extract and analyze survival data from imatinib-treated PDGFRA eosinophilia cohorts."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Pardanani 2003) → runPythonAnalysis (pandas survival plot) → matplotlib figure of remission rates.
"Draft LaTeX review on imatinib dosing for FIP1L1-PDGFRA HES."
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro) → latexSyncCitations (Gotlib 2003, Klion 2015) → latexCompile → PDF with response predictor table.
"Find code for PDGFRA fusion detection from related papers."
Research Agent → searchPapers (eosinophilia genomics) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → NGS pipeline for CHIC2 deletion analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ imatinib HES papers: searchPapers → citationGraph → GRADE grading → structured report on PDGFRA outcomes. DeepScan applies 7-step analysis with CoVe checkpoints to verify Pardanani (2003) claims against Valent (2012) classifications. Theorizer generates hypotheses on imatinib-mepolizumab combinations from Rothenberg (2008) and Klion (2015) data.
Frequently Asked Questions
What defines PDGFRA-associated eosinophilia responsive to imatinib?
FIP1L1-PDGFRA fusion or CHIC2 deletion identifies cases with near-complete responses to imatinib at 100-400 mg daily (Pardanani et al., 2003; Gotlib et al., 2003).
What methods confirm PDGFRA rearrangements?
RT-PCR detects FIP1L1-PDGFRA fusion; FISH or array CGH identifies CHIC2 deletion as surrogate (Pardanani et al., 2003; Valent et al., 2012).
What are key papers on imatinib in this area?
Pardanani et al. (2003; Blood, 394 citations) links CHIC2 to imatinib response; Gotlib et al. (2003; Blood, 286 citations) details fusion implications; Klion (2015; Blood, 273 citations) reviews HES treatment.
What open problems exist?
Resistance mechanisms, optimal combinations with biologics like mepolizumab, and long-term outcomes in pediatric PDGFRA eosinophilia lack prospective trials (Klion, 2015; Rothenberg et al., 2008).
Research Eosinophilic Disorders and Syndromes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Imatinib Mesylate Treatment for PDGFRA-Associated Eosinophilia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers